<DOC>
	<DOC>NCT02928263</DOC>
	<brief_summary>A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents</brief_summary>
	<brief_title>Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<criteria>Diagnosis with metastatic renal cell carcinoma Prescription/administration of one of the IV or oral agents examined in the study Patients with other primary cancer diagnosis before RCC diagnosis Patients with pregnancy or HIV/AIDS</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>